BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,625,627 | -74.6% | 327,100 | -83.4% | 0.13% | -77.9% |
| Q2 2023 | $33,947,640 | +667.4% | 1,973,700 | +639.7% | 0.60% | +607.1% |
| Q1 2023 | $4,423,826 | +286.0% | 266,817 | +132.0% | 0.08% | +431.2% |
| Q3 2022 | $1,146,000 | +0.9% | 115,000 | -8.0% | 0.02% | 0.0% |
| Q2 2022 | $1,136,000 | -6.7% | 125,000 | +4.2% | 0.02% | +14.3% |
| Q1 2022 | $1,217,000 | -96.9% | 120,000 | -94.9% | 0.01% | -96.8% |
| Q4 2021 | $39,095,000 | +421.3% | 2,343,851 | +1364.9% | 0.44% | +410.5% |
| Q3 2021 | $7,499,000 | +48.3% | 160,000 | +92.8% | 0.09% | +30.3% |
| Q2 2021 | $5,058,000 | +24.4% | 83,000 | +25.8% | 0.07% | -24.1% |
| Q1 2021 | $4,067,000 | +75.9% | 66,000 | +103.1% | 0.09% | +64.2% |
| Q4 2020 | $2,312,000 | +64.3% | 32,500 | -13.3% | 0.05% | +60.6% |
| Q3 2020 | $1,407,000 | -79.6% | 37,500 | -82.3% | 0.03% | -85.7% |
| Q2 2020 | $6,898,000 | +137.9% | 211,500 | +111.5% | 0.23% | +40.2% |
| Q1 2020 | $2,900,000 | – | 100,000 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |